Sanofi and Earendil Labs forge $2.56bn autoimmune deal
GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing and payer acceptance challenges remain.
Autoimmune Disorders
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
AbbVie extends Rinvoq exclusivity by four years after generics settlements
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Vor Bio back from brink with autoimmune drug deal rising to $4bn
